Elkin Gregory, Prigozhina Tatyana B, Slavin Shimon, Gurevitch Olga, Khitrin Sofia, Resnick Igor B
Am J Blood Res. 2011;1(2):110-8. Epub 2011 Aug 22.
Donor Lymphocyte Infusion (DLI) is a well-recognized tool for augmentation of the anti-leukemia effect after mismatched bone marrow transplantation. Experimental results show, however, that DLI efficacy is strongly dependent on the number of donor hematopoietic cells persisting in recipient after transplantation. It is strong in mixed chimeras and relatively weak in full chimeras (FC) that replace host antigen-presenting cells by donor antigen-presenting cells. In this study we applied a new in vivo cytotoxicity monitoring method for evaluation of the changes in FC anti-host immunity after co-transplantation of donor and host hematopoietic cells together.
Full hematopoietic chimeras and naïve control mice were transplanted with a mixture of equivalent numbers of donor and recipient or donor and third party splenocytes labeled by a cell-permeable fluorescent dye CFDA-SE. The animals were sacrificed at various time points, and their splenocyte suspensions were prepared, depleted of red blood cells, stained with allophycocyanin-labeled anti-H2(b) antibodies, and analyzed using fluorescence-activated cell sorting. The immune response was assessed according to the percentage of single positive CFDA-SE(+)/ H2(b-) cells of all CFDA-SE(+) cells.
FC grafted with splenocytes from similar FC mixed with splenocytes from naïve host-type or third-party-type mice rejected host cells within 14 days, and third-party cells within 7 days. NK cell depletion in vivo had no influence on host cell rejection kinetics. Co-infusion of host-type splenocytes with splenocytes obtained from naïve donor-type mice resulted in significant acceleration of host cell rejection (10 days). Naïve mice rejected the same amount of allogeneic lymphocytes within 3 days.
Proposed method provides a simple and sensitive tool to evaluate in vivo post-transplant cytotoxicity in different experimental settings. The method demonstrates that FC is specifically deficient in their ability to reject host lymphocytes even when antigen-presenting host cells are provided. DLI improve anti-host immune response in FC but can not restore it to the level observed in naïve donor-type mice.
供体淋巴细胞输注(DLI)是一种公认的用于增强不匹配骨髓移植后抗白血病效应的手段。然而,实验结果表明,DLI的疗效在很大程度上取决于移植后受体中持续存在的供体造血细胞数量。在混合嵌合体中效果较强,而在供体抗原呈递细胞取代宿主抗原呈递细胞的完全嵌合体(FC)中相对较弱。在本研究中,我们应用了一种新的体内细胞毒性监测方法,以评估供体和宿主造血细胞共同移植后FC抗宿主免疫的变化。
将等量的供体和受体或供体和第三方脾细胞用细胞可渗透的荧光染料CFDA-SE标记后混合,移植到完全造血嵌合体和未处理的对照小鼠体内。在不同时间点处死动物,制备脾细胞悬液,去除红细胞,用别藻蓝蛋白标记的抗H2(b)抗体染色,并用荧光激活细胞分选进行分析。根据所有CFDA-SE(+)细胞中单一阳性CFDA-SE(+)/H2(b-)细胞的百分比评估免疫反应。
移植了来自相似FC的脾细胞与来自未处理的宿主型或第三方型小鼠的脾细胞的FC,在14天内排斥宿主细胞,在7天内排斥第三方细胞。体内NK细胞耗竭对宿主细胞排斥动力学没有影响。将宿主型脾细胞与从未处理的供体型小鼠获得的脾细胞共同输注,导致宿主细胞排斥显著加速(10天)。未处理的小鼠在3天内排斥相同数量的同种异体淋巴细胞。
所提出的方法提供了一种简单且灵敏的工具,用于评估不同实验环境下移植后的体内细胞毒性。该方法表明,即使提供了抗原呈递的宿主细胞,FC在排斥宿主淋巴细胞的能力上也存在特异性缺陷。DLI可改善FC中的抗宿主免疫反应,但无法将其恢复到未处理的供体型小鼠中观察到的水平。